InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th
July 31 2008 - 9:30AM
PR Newswire (US)
BRITISH COLUMBIA, Canada, July 31 /PRNewswire-FirstCall/ -- InNexus
Biotechnology Inc., (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF)
(http://www.ixsbio.com/), a drug development company
commercializing the next generation of monoclonal antibodies based
on its Dynamic Cross Linking (DXL(TM)) technology, will present at
IBC's 13th Annual World Congress Drug Discovery & Development
of Innovative Therapeutics (DDT) Conference being held in Boston at
the World Trade Center Boston & Seaport Hotel. The InNexus
presentation will be within the Main Conference beginning at 9:40
AM (ET) on Wednesday, August 6th, held in the amphitheater at the
World Trade Center Boston. Dr. Thomas Kindt, Chief Scientific
Officer will present an in-depth presentation on a Case Study of
InNexus' preclinical candidate DXL625 (CD20): A New Platform for
Augmenting Antibody Therapeutics for Cancer. Chairman and CEO, Jeff
Morhet will also provide a company overview, including information
about InNexus' unique business strategy, its DXL(TM) technology
platform and upcoming company milestones. Investors, venture
capitalists, company executives, scientists and other industry
leaders will attend the conferences. About InNexus InNexus is a
drug development company commercializing the next generation of
monoclonal antibodies based on its DXL(TM) technology, which
improves the potency of existing antibody products while opening
new markets and disease applications. DXL(TM) antibodies utilize
unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal
management based in Scottsdale, Arizona on the campus of Mayo
Clinic and has its own in-house developmental facilities. These
development resources provide validation of protein and peptide
discoveries, enabling InNexus (and its strategic partners) to
advance novel drug therapeutics and diagnostics. To learn more
about InNexus, please visit http://www.ixsbio.com/. The TSX Venture
Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this news release. This news release
may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are
subject to factors, many of which are beyond the Company's control,
that may cause actual results or performance to differ materially
from those currently anticipated in such statements. DATASOURCE:
InNexus Biotechnology Inc. CONTACT: Jeff Morhet, Chairman &
Chief Executive Officer of InNexus Biotechnology Inc.,
+1-480-862-7500 Web site: http://www.ixsbio.com/
Copyright